BUTORPHANOL TARTRATE IS BETTER THAN FENTANYL FOR POSTOPERATIVE ANALGESIA AFTER INTESTINAL SURGERY: A PROSPECTIVE COHORT STUDY

CURRENT STATUS: UNDER REVIEW

Bo Hu
Wuhan University Zhongnan Hospital

Zhi-Li Wang
Wuhan Women and Children Medical Care Center

Jing Wang
Wuhan University Zhongnan Hospital

Hui Xiang
Wuhan University Zhongnan Hospital

Yu-Qian Zhao
Wuhan University Zhongnan Hospital

Zhi-Yong Peng pengzy5@hotmail.com
Wuhan University Zhongnan Hospital

Corresponding Author
ORCiD: 0000-0002-3873-9607

DOI: 10.21203/rs.2.9276/v1

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
analgesia, butorphanol tartrate, fentanyl, gastrointestinal function, intestinal surgery
Abstract

Background Traditional opioid analgesics act on the \( \mu_2 \) receptors and lead to delayed gastric emptying and weakening of the peristalsis. Butorphanol is an opioid analgesic that has strong excitatory effect on \( \kappa \) receptors, weak \( \mu \) receptor agonistic and antagonistic activity. This study aimed to compare the effects of butorphanol tartrate and fentanyl on the analgesia and the gastrointestinal motility after intestinal surgery.

Method This prospective cohort study was conducted in Zhongnan Hospital of Wuhan University, Wuhan, China from May to September 2017. One hundred and forty six patients admitted to ICU after intestinal surgeries, were divided into fentanyl group and butorphanol group. The fentanyl group continually infused fentanyl with 1ug/kg/h and the butorphanol group continually infused butorphanol with 20ug/kg/h. The analgesics were used until the patients were transfer out of ICU or up to 24 hours. The primary outcome was the time required for the first passage of flatus. The second outcomes included the pain and sedation scores, the incidence of nausea and vomiting, serum motilin concentrations, and the incidence rate of adverse reactions.

Results There were 69 patients in butorphanol group and 77 patients in fentanyl group. Compared with the fentanyl group, the time required for the first passage of flatus was shorter (69.82 ±18.84 h vs. 79.34 ± 15.69 h, \( p = 0.0012 \)) and the incidence of nausea (14.9% vs. 29.3%, \( P=0.013 \)) and vomiting (11.7% vs. 27.3%, \( P=0.031 \)) was significantly lower in the butorphanol group without any significant difference in analgesic score and sedation score. The serum motilin increase level was significantly higher in butorphanol group 21.36(6.17, 28.47) ng/L vs. 5.56(3.04, 9.81) ng/L, \( P = 0.034 \)

Conclusion: In patients undergoing intestinal surgery, butorphanol tartrate allows faster recovery of gastrointestinal function and similar analgesia compared to fentanyl.

TRIAL REGISTRATION Chinese Clinical Trial Register (ChiCTR-INR-17011031). Registered on
Mar 31th 2017.

Background

Continuous intravenous analgesia is an effective method for relieving pain, antagonizing stress and reducing oxygen consumption. It has become one of the preferred methods for providing postoperative analgesia ADDIN EN.CITE [1, 2] . However, one of the major concerns with these analgesics is their side effects, especially inhibition of intestinal motility. Traditional opioid analgesics act on the μ2 receptors and lead to delayed gastric emptying and weakening of the peristalsis. The most commonly reported gastrointestinal side-effects include nausea, vomiting and abdominal distention ADDIN EN.CITE [3-5] . Butorphanol is a lipid soluble opioid analgesic which can be used intravenously, intrathecally as well as for epidural analgesia. It has strong excitatory effect on κ receptors, weak μ receptor agonistic and antagonistic activity, and minimal effect on the σ receptors ADDIN EN.CITE [6, 7] . Due to the mild μ2 receptor agonist activity, the gastrointestinal side-effects of butorphanol are believed to be lesser than that of the traditional opioids ADDIN EN.CITE [8] . It has been used alone ADDIN EN.CITE [9] , in combination with dexmedetomidine ADDIN EN.CITE [10] , dezocine ADDIN EN.CITE [9] ] for patient-controlled analgesia in the postoperative period after laparoscopic surgeries. It has also been used preoperatively in combination with flurbiprofen axetil to attenuate remifentanil-induced hyperalgesia ADDIN EN.CITE [11] . Some researchers have also used butorphanol in combination with ropivacaine or bupivacaine via thoracic epidural catheter for postoperative analgesia after abdominal surgeries ADDIN EN.CITE [12, 13] . In this context, butorphanol was found to have lesser gastrointestinal side-effects compared to fentanyl [14]. However, there is little data on the effect of intravenous butorphanol infusion of the gastrointestinal motility. Hence, we conducted this study to compare the effects of butorphanol tartrate and the traditional opioid analgesics (fentanyl) on the
gastrointestinal motility after intestinal surgery.

Methods

Patient selection

This prospective study was conducted in the Intensive Care Unit (ICU), Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China from May 2017 to September 2017. Inclusion criteria were: (1) patients admitted to ICU after elective intestinal surgery; (2) under general anesthesia and transferred into ICU with intubation, expected to stay in ICU at least 12 hours; (3) age 18-85 years; (4) weight 45-80 kg; (5) ASA I – II. Exclusion criteria were: 1) patients with known allergies to butorphanol or other drugs used in this study; 2) long-term use of narcotic analgesics, sedatives, antidepressants, non-steroidal anti-inflammatory drugs; 3) persistent systemic hypotension and poor tissue perfusion despite the use of vasopressors; 4) acute severe brain injury; 5) severe cardiac, respiratory, liver and kidney dysfunction; 6) patients who participated or are participating in other drug trials in last 3 months.

This study conforms to the standards of medical ethics and has been approved by the ethics committee of Zhongnan Hospital of Wuhan University (ethical approval number – 2017026). This study was registered in Chinese Clinical Trial Register (ChiCTR-INR-17011031), registered on Mar 31th 2017. Written informed consent was obtained from each patient or his/her family member.

Process

Patients after intestinal surgery who satisfied the above criteria were included in the study and given intravenous analgesia postoperatively in the ICU. The patients were divided into fentanyl group and butorphanol tartrate group based on the initial analgesic drug used by the clinicians. In the fentanyl group, 500ug of fentanyl was diluted with 50ml of normal saline, started at 1ug/kg/h and maintained at 0.5-2ug/kg/h. In the butorphanol
tartrate group, butorphanol tartrate injection 20mg was diluted with normal saline 50ml, started at 20ug/kg/h and maintained at 10-30ug/kg/h. In both groups, continuous intravenous analgesia was administered using micro-pump until the patients were transferred out of ICU or up to 24 hours. The degree of patients’ analgesia was judged using the Critical Care Pain Observation Tool (COPT) score. The target score was set at 0-1. If the score was more than 1, the infusion rate was accordingly adjusted.

Sedation protocol: No sedation was used initially. The Richmond Agitation-Sedation Scale (RASS) score used to assess sedation. The ideal target score was set between -2 to 0 point. If RASS score above 1 point (including 1 point), sedation was given. The choice of sedative drugs was based on clinician's experience.

Variables

Primary outcome: time of first passage of flatus after operation (from ICU admission after surgery to first passage of flatus). To ensure the accuracy for timing the first passage of flatus, we educated the patients how to record the time both at extubation and transferring out of ICU. The study investigators visited the patients every 12h (7am, 7pm) to record the time (measured at hours) until the first passage of flatus had occurred.

Secondary outcomes:

(1) The pain scores (CPOT score) and sedation scores (RASS score) at 1h, 6h, 12h and 24h after surgery

(2) The total amount of analgesic drugs and sedative drugs used in the postoperative period.

(3) The incidence and severity of postoperative nausea and vomiting. Nausea was evaluated as follows: 0 point for no nausea, 1 point for a mild nausea at rest and 2 for severe nausea at rest. Vomiting was assessed as follows: 0 for no vomiting, 1 for mild vomiting (1~2 times a day), and 2 for severe vomiting (more than 3 times a day).
(4) Intestinal barrier function and serum motilin concentration before the use of analgesic drugs and 12 hours after their use.

(5) Recovery of oral feeding after operation (from ICU to the first time of oral feeding).

(6) The incidence rate of cardiorespiratory adverse reactions. It included hypertension (systolic pressure >140 mmHg or diastolic pressure >90 mmHg or higher than normal level of 20%); hypotension (systolic pressure <90 mmHg or diastolic <60 mmHg or decreased by 20% more than normal level); respiratory depression (respiratory frequency less than 10 times per minute); tachycardia (heart rate more than 110 times per minute); bradycardia (heart rate less than 50 times per minute).

**Measurement**

Three milliliters of venous blood samples were collected from patients before the use of analgesic drugs and at 12 hours after their use, and 1ml was directly used to detect the Intestinal barrier function biochemical indicators (D-lactic acid, diamine oxidase, endotoxin) by the JY-DLT intestinal barrier function biochemical index analysis system (Zhongsheng Jinyu, Beijing, China); The other 2ml were centrifuged at 2,000 g for 20 minutes and the serum fraction was frozen and stored at −80°C until analyzed. The serum motilin concentrations were measured using enzyme-linked immunosorbent assay (ELISA) with a commercially available kit (Huamei, Wuhan, China).

**Statistical analysis**

For the primary outcome, we hypothesized that butorphanol tartrate group would be noninferior to fentanyl group for analgesia based on a normal distribution for the difference in proportions between groups. The trial would have at least 80% power to detect a between-group difference of 10-flatus recovery-hour and to declare noninferiority on the basis of a predefined noninferiority margin of 10 percentage points, with an overall alpha of 0.05. We initially determined that with 63 patients in each group, with an
estimate of 10% loss, the sample size would be 70 for each group and approximately 140 for sum.

All the data were analyzed using SPSS version 22.0. The categorical data were assessed using chi-square test. The continuous data were compared by rank sum test or T test. All the statistical tests were conducted using bilateral tests. The P value of less than or equal to 0.05 was considered to be statistically significant. t-test or chi-square test was used to compare demographic data and other basic value indicators to determine the two groups of equilibrium levels. T test or rank sum test were used to evaluate the validity index. Safety analysis, such as the time, frequency of adverse events, and the incidence of adverse reactions in the both groups were analyzed by chi-square test.

Results

Comparison of patient characteristics

In this study, 216 patients were recruited and 146 patients were finally included (Fig 1). All patients were under general anesthesia and transferred into ICU with intubation. The number of butorphanol tartrate group was 69 and fentanyl group was 77. There were no significant differences in gender, age, height, weight, past medical history, acute physiology chronic health status score system II (APACHE II) score, surgical site, surgical technique and time course of ventilation between the two groups (P>0.05) (Table 1).

Comparison of the time required for first passage of flatus and for resumption of oral feeding

The duration from ICU admission to the first passage of flatus was significantly shorter in butorphanol group (69.82 ±18.84 h vs. 79.34 ± 15.69 h, p= 0.0012). The time required for resumption of oral feeding of liquid diet was also shorter in butorphanol group (108.64 + 18.82 h vs 94.40 + 20.46 h, p<0.001).

Comparison of the analgesic effect
 Compared with the fentanyl group, the CPOT score before starting medication was significantly higher in the butorphanol group (P<0.05). There was no significant difference in the COPT score between the two groups at 1h, 6h, 12h and 24h after the initiation of the medication (P>0.05) (Table 2). However, the CPOT scores at different time points in both groups were significantly lower than those before starting the medications (P<0.05) (Table 2). The dosage of analgesic drugs in two groups was shown in Table 4.

Comparison of the sedation score (RASS score)

Due to good analgesia and smooth removal of the tracheal intubation sedative drugs were only used in one patient in butorphanol group (propofol -1) and two patients in fentanyl group (midazolam -2) (Table 4). The comparison of RASS score between two groups was shown in table 3.

Comparison of intestinal barrier function and serum motilin levels

The D-lactic acid, diamine oxidase, endotoxin and serum motilin concentrations before starting the medications were similar in the two groups (Table 5). There was statistically significant difference between diamine oxidase concentration 12h after starting the medication in butorphanol group and fentanyl group (P<0.05). The other indexes, such as the D-lactic acid, endotoxin before and 12h after medication were similar (P>0.05). The serum motilin concentration 12h after medication in two groups was significantly higher than that before medication. There was no significant difference in serum motilin concentration before and 12h after medication in the two groups (Table 5). However, the level of increase in serum motilin in the butorphanol group was significantly higher than that in the fentanyl group [21.36(6.17, 28.47) vs. 5.56(3.04, 9.81), (P = 0.034)].

Comparison of the incidence of nausea and vomiting

Most of the patients had no nausea before the start of medication. There was significant increase in the incidence of nausea at 6h and 12h after starting medications in both
groups. The proportion of patients at 6h (6.0% vs. 20.0%, P=0.006) and 12h (14.9% vs. 29.3%, P=0.013) with nausea was significantly higher in the fentanyl group as shown in Table 6. The incidence of vomiting in the butorphanol group was significantly lower than that in fentanyl group at 24h after starting medications (11.7% vs. 27.3%, P=0.031) (Table 7).

Comparison of the adverse reactions after analgesic medications

Compared with the fentanyl group, there was no significant difference in the incidence of hypertension, hypotension, tachycardia and bradycardia in the butorphanol group (P>0.05). The incidence of respiratory depression was lower in the butorphanol group but failed to reach statistical significance (10.1% vs. 22.1%, P=0.052). (Table 8).

Discussion

In this study, we found that use of butorphanol tartrate infusion in the immediate postoperative period after intestinal surgery was associated with lesser time for the passage of flatus, lower incidence of nausea and vomiting with similar analgesic effects compared to fentanyl infusion.

Traditionally used opioid drugs (such as morphine and fentanyl) stimulate the μ1 receptors which has the analgesic effect as well as the μ2 receptors which are widely distributed throughout the gastrointestinal tract, resulting in adverse reactions including nausea, vomiting, abdominal distention, and delayed transit time. On the other hand, butorphanol tartrate is different from traditional opioids, has both agonistic and antagonistic effects on opioid receptors; it has an exciting effect on kappa receptors, both agonistic and antagonistic action on the μ receptors, and low binding force with σ receptors ADDIN EN.CITE [6]. Its binding force with κ:μ:σ receptor is 25: 4: 1 [7]. Due to its minimal effect on the μ2 receptors, butorphanol tartrate has lesser impact on the gastrointestinal motility compared to the traditional opioids.
After any intestinal surgery, there is gastrointestinal dysfunction in the postoperative period due to general anesthesia, altered intestinal barrier and structural changes, the incidence of which can reach up to 40% ADDIN EN.CITE [4] . In ICU, concurrent gastrointestinal dysfunction can significantly prolong the duration of mechanical ventilation and ICU stay ADDIN EN.CITE [15] . Therefore, patients undergoing intestinal surgery should have recovery of their gastrointestinal functions as soon as possible. In this study, we found that, compared with the traditional opioid fentanyl, butorphanol tartrate can shorten the time required for first passage of flatus, hasten the feeding process, and reduce the proportion and severity of vomiting. These effects might be related to the increased levels of serum motilin by butorphanol tartrate.

Fentanyl predominantly activates $\mu$ receptors and is 100 times more effective than morphine. On the other hand, butorphanol tartrate mainly acts on $\kappa$ receptor, and has double inhibitory effect on $\mu$ receptor. Its analgesic effect is 5 times that of morphine [16].

In this study, we found both fentanyl and butorphanol to have good analgesic effect as suggested by significant decrease in the CPOT score after starting the medications (Table 2). Moreover, there was no significant difference in the CPOT score at any time of the treatment between the two groups, indicating that the analgesic effect of the two drugs was similar.

With regards to the dose of analgesic drugs used, in the fentanyl group, the mean dosage was 1.05 mg per person, equivalent to the use of 105.0 mg morphine while in the butorphanol group, the mean dosage was 24.58 mg per person, equivalent to the use of 122.9 mg morphine. This shows that the analgesic activity of butorphanol tartrate is no less than that of fentanyl for postoperative analgesia in patients undergoing gastrointestinal surgery.

Based on the iPAD guidelines ADDIN EN.CITE [17] , the use of sedative drugs in the
postoperative period can be reduced by providing good analgesia. In our study, due to good analgesic effect of both fentanyl and butorphanol, there was almost no need of sedative in the two groups, and the RASS score of the two groups at any time were in the ideal range from -1 to 0.

Opioid analgesics have multiple adverse effects including inhibition of intestinal motility leading to nausea, vomiting, constipation, cardiac dysfunction affecting heart rate, blood pressure and respiratory depression. Our study found that no significant difference in the effect of fentanyl and butorphanol infusion on blood pressure and heart rate of the patients (Table 8). However, the incidence of respiratory depression was higher in the fentanyl group though not statistically significant due to small sample size (Table 8). Fentanyl activates the $\mu_2$ receptors, and acts on the ventrolateral medulla to suppress respiratory impulses and slow down the respiratory rhythm [18, 19]. Additionally, the traditional opioids can also induce respiratory inhibition by causing chest wall muscle stiffness [20]. Conversely, butorphanol predominantly acts on $\kappa$ receptor which has little influence on respiration. Hence, the inhibition of respiration by butorphanol was less than fentanyl.

Our study has some limitations. First, it was a prospective cohort study and not a randomized controlled study leading to possibility of selection bias. Second, the sample size was small and it was a single center study. Future multicenter studies with larger sample size are required to validate our findings. Third, the effect of intraoperative anesthetic drugs on the postoperative analgesia was not analyzed and excluded. Moreover, most of the variables to evaluate the primary outcome were from the patients’ subjective descriptions although serum motilin was also very useful to explain the phenomenon. Further research should aim at improving the above limitations in order to get more convincing results.
Conclusion

Butorphanol tartrate has good postoperative analgesic effect after gastrointestinal surgery similar to that of fentanyl with shorter time for recovery of bowel motility and lower incidence of nausea and vomiting.

Abbreviations List

ICU: Intensive Care Unit
CPOT: Critical Care Pain Observation Tool
RASS: Richmond Agitation-Sedation Scale
ELISA: enzyme-linked immunosorbent assay
APACHE II: acute physiology chronic health status score system II

Declarations

Ethics approval and consent to participate

This study conforms to the standards of medical ethics and has been approved by the ethics committee of Zhongnan Hospital of Wuhan University (ethical approval number – 2017026). This study was registered in Chinese Clinical Trial Register (ChiCTR-INR-17011031), registered on Mar 31th 2017. Written informed consent was obtained from each patient or his/her family member.

Consent for publication

Not applicable

Availability of Data and Materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors declare that they have no competing interests
Funding

This work was supported by the Clinical research and development project of Hubei Provincial Health and Family Planning Commission (BH, WJ2017H0009, for data collection), the National Natural Science Foundation of China (ZP, 81560131, for data collection) and Hubei Science and Technology Bureau Key Projects (ZP, 2017AHB044, for data analysis).

Authors' contributions

BH and ZP designed this study and protocol development: ZW, JW, HX, and YZ were responsible for patient recruitment, data extraction and analysis. BH & ZP conducted the manuscript writing. All authors read and gave their approval for the final version of the manuscript.

Acknowledgements

We would like to express our sincere appreciation toward Mr Rahul Gupta from Majedan Co. for the revise of manuscript.

References

1. Devlin JW, Skrobik Y, Gelines C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B et al: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical care medicine 2018, 46(9):e825-e873.
2. Lutz A, Spies C: [ICU delirium: Consequences for management of analgesia and sedation in the critically ill]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 2011, 46(9):568-572.
3. Ehieli E, Yalamuri S, Brudney CS, Pyati S: Analgesia in the surgical intensive care unit. Postgraduate medical journal 2017, 93(1095):38-45.
4. Muller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, Emmanuel A, Laroche F, Meissner W, Morlion B: Opioid-Induced Constipation and Bowel Dysfunction: A
Clinical Guideline. *Pain medicine (Malden, Mass)* 2017, 18(10):1837-1863.

5. Pappagallo M: Incidence, prevalence, and management of opioid bowel dysfunction. *American journal of surgery* 2001, 182(5A Suppl):11s-18s.

6. Bidlack JM: Mixed kappa/mu partial opioid agonists as potential treatments for cocaine dependence. *Advances in pharmacology (San Diego, Calif)* 2014, 69:387-418.

7. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. *Journal of pharmacological sciences* 2005, 98(2):109-116.

8. Sellon DC, Monroe VL, Roberts MC, Papich MG: Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses. *American journal of veterinary research* 2001, 62(2):183-189.

9. Ren BX, Zong J, Tang JC, Sun DP, Hui X, Li RQ, Zhang JL, Ji Y: Effects of intravenous analgesia with combined dezocine and butorphanol on postoperative cognitive function in elderly patients. *Genetics and molecular research : GMR* 2015, 14(2):5571-5576.

10. Zhang XK, Chen QH, Wang WX, Hu Q: Evaluation of dexmedetomidine in combination with sufentanil or butorphanol for postoperative analgesia in patients undergoing laparoscopic resection of gastrointestinal tumors: A quasi-experimental trial. *Medicine* 2016, 95(50):e5604.

11. Zhang L, Shu R, Zhao Q, Li Y, Yu Y, Wang G: Preoperative butorphanol and flurbiprofen axetil therapy attenuates remifentanil-induced hyperalgesia after laparoscopic gynaecological surgery: a randomized double-blind controlled trial. *British journal of anaesthesia* 2016, 117(4):504-511.

12. Swathi N, Ashwini N, Shukla MI: Comparative study of epidural bupivacaine with butorphanol and bupivacaine with tramadol for postoperative pain relief in abdominal surgeries. *Anesthesia, essays and researches* 2016, 10(3):462-467.
13. Babu S, Gupta BK, Gautam GK: A Comparative Study for Post Operative Analgesia in the Emergency Laparotomies: Thoracic Epidural Ropivacaine with Nalbuphine and Ropivacaine with Butorphanol. *Anesthesia, essays and researches* 2017, 11(1):155-159.

14. Kumar A, Kumar R, Verma VK, Prasad C, Kumar R, Kant S, Kumar G, Singh N, Kumari R: A randomized controlled study between fentanyl and Butorphanol with low dose intrathecal bupivacaine to facilitate early postoperative ambulation in urological procedures. *Anesthesia, essays and researches* 2016, 10(3):508-511.

15. Zhao Y, Wang J, Liu Z, Lin H, Shi Y, Sun X: Pulmonary dysfunction in 114 patients with inflammatory bowel disease. *Medicine* 2017, 96(18):e6808.

16. Lin L, Liu S, Chen Z, Lin S: Effect of ketamine combined with butorphanol on emergence agitation of postoperative patients with gastric cancer. *Therapeutics and clinical risk management* 2016, 12:713-717.

17. Barr J, Fraser GL, Punttilo K, Ely EW, Gelinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM et al: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Critical care medicine* 2013, 41(1):263-306.

18. Qi J, Li H, Zhao TB, Lu YC, Zhang T, Li JL, Dong YL, Li YQ: Inhibitory Effect of Endomorphin-2 Binding to the mu-Opioid Receptor in the Rat Pre-Botzinger Complex on the Breathing Activity. *Molecular neurobiology* 2017, 54(1):461-469.

19. Montandon G, Qin W, Liu H, Ren J, Greer JJ, Horner RL: PreBotzinger complex neurokinin-1 receptor-expressing neurons mediate opioid-induced respiratory depression. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2011, 31(4):1292-1301.

20. Liu X, Zou Y, Zhao J, Huang Y: Emergency scenario of fentanyl induced faciocervical rigidity and complete upper airway obstruction during anesthesia induction. *Chinese
Tables

Table 1. Comparison of patient characteristics

|                          | Butorphanol (n=69) | Fentanyl (n=77) | Test statistic |
|--------------------------|--------------------|-----------------|----------------|
| Sex (M/F, n)            | 40/29              | 42/35           | 0.173          |
| Age (y, `x± s)          | 61.29±13.02        | 62.18±11.54     | -0.439         |
| Height(cm, `x± s)       | 165.91±9.10        | 165.74±8.05     | 0.122          |
| Weight (kg, `x± s)      | 65.09±7.22         | 63.78±5.61      | 1.212          |
| APACHE II score(x± s)   | 5.54±1.82          | 5.22±2.25       | 0.936          |
| Hypertension(Y/N, n)    | 19/ 50             | 27 / 50         | 0.956          |
| Coronary artery disease(Y/N, n) | 5 / 64       | 3 / 74         | 0.023          |
| Diabetes(Y/N, n)        | 6 / 63             | 8 / 69          | 0.120          |
| Smoking(Y/N, n)         | 16 / 53            | 12 / 65         | 1.357          |
| Alcohol(Y/N, n)         | 3 / 66             | 6 / 71          | 0.165          |
| Surgical site (n)       |                    |                 |                |
| duodenum and small bowel| 8                  | 10              | 0.065          |
| Colon                   | 33                 | 38              | 0.034          |
| Rectum                  | 28                 | 29              | 0.130          |
| Surgical technique(open/lap, n) | 42 / 27   | 42 / 35         | 0.364          |
| Time course of ventilation(hour, x± s) | 7.32±3.37    | 7.13±2.30       | 0.391          |

APACHE II score: acute physiology and chronic health score II;

Table 2. Comparison of analgesic effect

| N  | CPOT score (x ± s) |                    |                  |                  |
|----|--------------------|---------------------|------------------|------------------|
|    |                    | Before medication   | 1h after          | 6h after          | 12h after         |
|    |                    |                     | medication       | medication       | medication       |
|    |                    |                     |                  |                  |                  |
| Butorphanol | 69 | 1.33±1.76       | a0.48±0.90       | a0.14±0.39       | a0.01±0.12       |
| Fentanyl    | 77 | 0.77±1.21       | a0.44±0.72       | a0.13±0.41       | a0.10±0.55       |

P 0.027 0.787 0.822 0.170
Compared with the COPT score before administering medications, $^aP<0.05$

Table 3. Comparison of RASS score

| N     | RASS Score (x ± s)                  | Before medication | 1h after medication | 6h after medication | 12h after medication |
|-------|-------------------------------------|-------------------|---------------------|---------------------|----------------------|
|       |                                     |                   |                     |                     |                      |
| Butorphanol 69 | -1.38±2.28                          | -0.48±1.35        | -0.23±0.81          | -0.10±0.55          |
| Fentanyl 77      | -1.69±1.97                          | -0.78±1.44        | -0.16±0.71          | 0.00±0.28           |
| Test statistics | 0.887                               | 1.301             | -0.606              | -1.387              |
| $P$ value        | 0.377                               | 0.195             | 0.545               | 0.169               |

Table 4. Dosage of analgesic and sedative drugs

| n  | Total dose (mg) | Dose adjusted [n (%)] | Addition of sedative drugs [n (%)] | Sedative drug Propofol (mg) |
|----|-----------------|-----------------------|------------------------------------|-----------------------------|
| Butorphanol 69 | 24.58±8.26 | 11 (15.9%)            | 1 (1.4%)                          | 320                         |
| Fentanyl 77      | 1.05±0.22      | 7 (9.1%)              | 2 (2.6%)                          | NA                          |

Table 5 Comparison of intestinal barrier function and plasma motilin level after medication
|                      | Before medication | 12h after medication | Before medication | 12h after medication | Before medication | 12h after medication | Before medication | 12h after medication |
|----------------------|-------------------|----------------------|-------------------|----------------------|-------------------|----------------------|-------------------|----------------------|
|                      |                   |                      |                   |                      |                   |                      |                   |                      |
| **D-lactic acid (mg/L)** |                   |                      |                   |                      |                   |                      |                   |                      |
| Butorphanol          | 35.74±13.82       | 28.86±14.77          | 26.06±17.92       | 19.75±14.39          | 9.67±8.32         | 4.74±5.55           | 49.93±23.28       | 70.78±36.78          |
| Fentanyl             | 32.48±11.75       | 30.72±13.87          | 28.33±16.46       | 25.84±15.55          | 9.39±5.79         | 7.08±6.04           | 48.43±21.01       | 54.44±27.14          |
| Test statistics      | 1.527             | -0.778               | -0.792            | -2.432               | 0.227             | -2.045              | -0.121            | -1.827               |
| **P value**          | 0.129             | 0.438                | 0.429             | 0.016                | 0.802             | 0.172               | 0.903             | 0.067                |

Compared with Before medications\[a\] P<0.05

Table 6 Comparison of nausea between the groups

|                      | Before medication [n(%)] | 1h after medication and before medication [n(%)] | 6h after medication before medication [n] |
|----------------------|--------------------------|-----------------------------------------------|-------------------------------------------|
|                      | 0 point                  | 1 point ↓                                     | 1 point ↑                                 | 1 point ↓         | 1 point ↑         |
| Butorphanol          | 67                       | 64(95.5%)                                    | 3(4.5%)                                   | 0(0%)             | 1(1.5%)          | 2(3.0%)           | 4(6.1)             |
| Fentanyl             | 75                       | 74(98.6%)                                    | 1(1.4%)                                   | 0(0%)             | 6(8.0%)          | 0(0%)             | 15(2)              |
| Test statistics      | /                        | 1.278                                        | 3.198                                     | 7.499             |                  |
| **P value**          | /                        | 0.258                                        | 0.073                                     | 0.006             |

1. Some patients were intubated before and 1h after medication, unable to evaluate nausea status.

2. Nausea score: 0 No nausea, 1 Mild nausea at rest, 2 Severe nausea at rest
Table 7 Comparison of vomiting between the groups

|                | Before medication [n (%)] | 24h after medication [n (%)] | 24h after (n) |
|----------------|---------------------------|-----------------------------|---------------|
|                | 0 point | 1 point | 0 point | 1 point | 2 points | 1 point ↓ |
| Butorphanol    | 68      | 67(98.6%) | 1(1.4%) | 61(88.4%) | 6(8.7%) | 2(2.9%) | 0(0%) |
| Fentanyl       | 77      | 75(97.4%) | 2(2.6%) | 56(72.7%) | 18(23.4%) | 3(3.9%) | 2(2.6%) |
| Test statistics| /       | 0.226    |          | 5.305    |            | 3.725   |
| P value        | /       | 0.634    |          | 0.021    |            | 0.054   |

1. Some patients were intubated before and 1h after medication, unable to evaluate vomiting status.

2. Vomiting score: 0 No vomiting, 1 Mild vomiting (1-2 times per day), 2 Severe vomiting (more than 3 times per day)

Table 8 Comparison of adverse reactions after medications

|                  | hypotension (n,%) | hypertension (n,%) | respiratory depression(n,%) | br.  |
|------------------|-------------------|-------------------|-----------------------------|------|
| Butorphanol (n=69) | 6(8.7%)           | 2(2.9%)           | 7(10.14%)                   | 4(↑) |
| Fentanyl (n=77)  | 2(2.6%)           | 4(5.19%)          | 17(22.08%)                  | 7(↑) |
| P value          | 0.149             | 0.684             | 0.052                       | 0.4  |

Figures
216 patients admitted to ICU after elective intestinal surgery

36 could not meet inclusion criteria
1 age<18 years
1 age>85 years
1 weight<45kg
3 weight>80kg
1 emergency surgery
3 admitted to ICU without intubation
26 expect stay in ICU<12h

14 met the specific exclusion criteria
4 long-term use of narcotic analgesics, sedatives, antidepressants, nonsteroidal anti-inflammatory drugs
10 severe cardiac, respiratory, liver and kidney dysfunction

166 patients were assessed for eligibility

83 were assigned to receive butorphanol
7 stay ICU<12h
5 consents withdrawn
2 withdrawn from care without infusion

69 patients analyzed

83 were assigned to receive fentanyl
3 stay ICU<12h
2 consents withdrawn
1 withdrawn from care without infusion

77 patients analyzed

Figure 1
The CONSORT flow diagram of patient enrollment. Abbreviation: ICU intensive care unit